ライフサイエンスコーパス: interferon-beta

1 i-inflammatory cytokines (interleukin 10 and interferon-beta).

2 gulate expression of SP100-related genes and interferon beta.

3 gnaling pathway, as determined by endogenous interferon beta.

4 repeated challenge by LPS if pretreated with interferon beta.

5 initial treatment with glatiramer acetate or interferon beta.

6 with the first line multiple sclerosis drug, interferon beta.

7 ve named L2 that regulates the expression of interferon-beta.

8 g to the activation of IRF3 and induction of interferon-beta.

9 e promotes Leishmania donovani infection via interferon-beta.

10 r probabilities of disability improvement as interferon beta (0.98 [0.65-1.49], p=0.93) and fingolimo

11 Treatment of CS-exposed ALI cultures with interferon beta-1 abrogated the viral infection, suggest

12 stratified by site, to receive subcutaneous interferon beta 1a 44 mug, intravenous alemtuzumab 12 mg

13 us alemtuzumab 12 mg per day or subcutaneous interferon beta 1a 44 mug.

14 187 (96%) of 195 patients randomly allocated interferon beta 1a and 376 (97%) of 386 patients randoml

15 202 (87%) of 231 patients randomly allocated interferon beta 1a and 426 (98%) of 436 patients randoml

16 40 (20%) patients in the interferon beta 1a group had sustained accumulation of d

17 20 (11%) of patients in the interferon beta 1a group had sustained accumulation of d

18 75 (40%) patients in the interferon beta 1a group relapsed (122 events) compared

19 104 (51%) patients in the interferon beta 1a group relapsed (201 events) compared

20 94 (47%) patients in the interferon beta 1a group were relapse-free at 2 years co

21 plan-Meier estimates, 59% of patients in the interferon beta 1a group were relapse-free at 2 years co

22 mpared with 134 [66%] of 202 patients in the interferon beta 1a group) that were mostly mild-moderate

23 adverse events compared with 12 (6%) in the interferon beta 1a group, and three (1%) had immune thro

24 e thrombocytopenia compared with none in the interferon beta 1a group.

25 fety of first-line alemtuzumab compared with interferon beta 1a in a phase 3 trial.

26 disability, comparing alemtuzumab 12 mg and interferon beta 1a in all patients who received at least

27 cacy and safety of alemtuzumab compared with interferon beta 1a in patients who have relapsed despite

28 Interferon beta 1a was given three-times per week and al

29 Interferon beta 1a was given three-times per week and al

30 mpared with three (2%) patients treated with interferon beta 1a.

31 uzumab versus 85 (45%) patients treated with interferon beta 1a.

32 rate was lower with daclizumab HYP than with interferon beta-1a (0.22 vs. 0.39; 45% lower rate with d

33 5% CI 43.2-60.7%) than patients treated with interferon beta-1a (15 of 66 patients, 27.2%, 17.2-41.4%

34 eeks was lower with daclizumab HYP than with interferon beta-1a (4.3 vs. 9.4; 54% lower number of les

35 ompared with 52 of 107 patients treated with interferon beta-1a (42.6%, 32.4-52.4%; hazard ratio [HR]

36 andomly assigned in a 1:1:1 ratio to receive interferon beta-1a (44 mug subcutaneously three times pe

37 gnificantly lower with ocrelizumab than with interferon beta-1a (9.1% vs. 13.6%; hazard ratio, 0.60;

38 se of either 1.25 or 0.5 mg or intramuscular interferon beta-1a (an established therapy for multiple

39 y and comparable safety of fingolimod versus interferon beta-1a (IFN beta-1a) in paediatric-onset mul

40 ertaken to determine whether combined use of interferon beta-1a (IFN) 30 mug intramuscularly weekly a

41 monotherapy in AFFIRM or in combination with interferon beta-1a (IFNbeta) in SENTINEL.

42 .25, or 5 mg/day), placebo, or intramuscular interferon beta-1a (IFNbeta-1a IM) during the core studi

43 t benefits of fingolimod 0.5 or 1.25 mg over interferon beta-1a (IFNbeta-1a) in patients with relapsi

44 arison, SPMS subjects from the intramuscular interferon beta-1a (IM IFNbeta-1a) IMPACT study were als

45 1.0 mg (n=447), ozanimod 0.5 mg (n=451), or interferon beta-1a (n=448).

46 eks was 16% with daclizumab HYP and 20% with interferon beta-1a (P=0.16).

47 mdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a - in patients hospitalized with coron

48 mod 1.0 mg or 0.5 mg or weekly intramuscular interferon beta-1a 30 mug.

49 mod 1.0 mg or 0.5 mg or weekly intramuscular interferon beta-1a 30 mug.

50 eficial effects of alemtuzumab compared with interferon beta-1a across all analysed patient subsets,

51 participants self-administered intramuscular interferon beta-1a as background anti-inflammatory treat

52 ose of 600 mg every 24 weeks or subcutaneous interferon beta-1a at a dose of 44 mug three times weekl

53 that has demonstrated superior efficacy over interferon beta-1a for relapsing-remitting multiple scle

54 nt-emergent adverse events was higher in the interferon beta-1a group (365 [83.0%] of 440 participant

55 mmon in the daclizumab HYP group than in the interferon beta-1a group (in 65% vs. 57% of the patients

56 More participants in the interferon beta-1a group had treatment-emergent adverse

57 in the ozanimod 0.5 mg group; and 36 in the interferon beta-1a group).

58 lizumab HYP group and in 10% of those in the interferon beta-1a group.

59 Pegylated interferon beta-1a has shown efficacy in a phase 3 trial

60 m the safety and efficacy of ozanimod versus interferon beta-1a in individuals with relapsing multipl

61 zumab reduced disease activity compared with interferon beta-1a in most of the analysed subgroups.

62 nd efficacy of ozanimod versus intramuscular interferon beta-1a in participants with relapsing multip

63 Efficacy of Natalizumab in Combination With Interferon Beta-1a in Patients With Relapsing-Remitting

64 ibody, is proven to be more efficacious than interferon beta-1a in the treatment of relapsing-remitti

65 se rate was lower with ocrelizumab than with interferon beta-1a in trial 1 (0.16 vs. 0.29; 46% lower

66 n was 0.02 with ocrelizumab versus 0.29 with interferon beta-1a in trial 1 (94% lower number of lesio

67 ment) significantly favored ocrelizumab over interferon beta-1a in trial 2 (0.28 vs. 0.17, P=0.004) b

68 on natalizumab monotherapy >18 months, 6 on interferon beta-1a monotherapy >36 months, and 5 untreat

69 interferon beta-1a, with rate ratios versus interferon beta-1a of 0.62 (95% CI 0.51-0.77; p<0.0001)

70 tes of disease activity and progression than interferon beta-1a over a period of 96 weeks.

71 uced compared with the previous 12 months of interferon beta-1a therapy (p<0.0001 for T2 lesions at b

72 olimod compared with the previous 12 months (interferon beta-1a to 0.5 mg fingolimod [n=167], 0.31 [9

73 s 0.22 [0.15-0.31], in months 13-24 p=0.049; interferon beta-1a to 1.25 mg fingolimod [n=174], 0.29 [

74 Switching from interferon beta-1a to fingolimod led to enhanced efficac

75 tients to assess the effect of a change from interferon beta-1a to fingolimod, and to compare over 24

76 Compared with patients switched from interferon beta-1a to fingolimod, continuous treatment w

77 s compared with the group that switched from interferon beta-1a to fingolimod, we recorded lower ARRs

78 tively evaluated the effect of intramuscular interferon beta-1a treatment following the first demyeli

79 enrolled in the Observational Study of Early Interferon beta-1a Treatment in High Risk Subjects after

80 ginally received 30 mug weekly intramuscular interferon beta-1a were randomly reassigned (1:1) to rec

81 umab HYP showed efficacy superior to that of interferon beta-1a with regard to the annualized relapse

82 gned to ozanimod 0.5 mg, and 441 assigned to interferon beta-1a) and 1138 (86.7%) completed 24 months

83 ozanimod 0.5 mg; and 11 [2.5%] who received interferon beta-1a).

84 ozanimod 0.5 mg; and 16 [3.6%] who received interferon beta-1a).

85 Adjusted ARRs were 0.35 (0.28-0.44) for interferon beta-1a, 0.18 (95% CI 0.14-0.24) for ozanimod

86 usly at a dose of 150 mg every 4 weeks, with interferon beta-1a, administered intramuscularly at a do

87 ion of disability compared with subcutaneous interferon beta-1a, and the mean expanded disability sta

88 however, in patients who initially received interferon beta-1a, ARR was lower after switching to fin

89 fingolimod at a dosage of 0.5 or 1.25 mg/d, interferon beta-1a, or placebo.

90 h ozanimod 0.5 mg, and 0.28 (0.23-0.32) with interferon beta-1a, with rate ratios versus interferon b

91 ng were higher with daclizumab HYP than with interferon beta-1a.

92 rophy in high risk CIS patients treated with interferon beta-1a.

93 t for all therapies apart from intramuscular interferon beta-1a.

94 ated a significantly lower relapse rate than interferon beta-1a.

95 bility after treatment with alemtuzumab than interferon beta-1a.

96 relapse rates and MRI outcomes compared with interferon beta-1a.

97 le sclerosis, as compared with intramuscular interferon beta-1a.

98 rate of clinical relapses than intramuscular interferon beta-1a.

99 crelizumab and in 2.9% of those treated with interferon beta-1a.

100 crelizumab and in 0.2% of those treated with interferon beta-1a.

101 0 mg (rate ratio [RR] of 0.52 [0.41-0.66] vs interferon beta-1a; p<0.0001), and 0.24 (0.19-0.31) for

102 for ozanimod 0.5 mg (RR 0.69 [0.55-0.86] vs interferon beta-1a; p=0.0013).

103 We tested whether interferon-beta-1a (IFN-beta-1a), which increases CD73 s

104 A combination of recombinant interferon beta-1b and lopinavir-ritonavir led to lower

105 Whether combined treatment with recombinant interferon beta-1b and lopinavir-ritonavir reduces morta

106 ere randomly assigned to receive recombinant interferon beta-1b plus lopinavir-ritonavir (interventio

107 linical trial comparing early versus delayed interferon beta-1b treatment in 465 patients with a CIS.

108 d to evaluate the impact of early vs delayed interferon beta-1b treatment in patients with clinically

109 In a patient cohort from the pivotal interferon beta-1b trial, the value of clinical and MRI

110 IL-17F before and early after treatment with interferon beta-1b was not associated with poor response

111 239 randomly selected patients treated with interferon beta-1b, 250 mug, for at least 2 years in the

112 Treatment with interferon beta-1b, 250 mug, for at least 2 years.

113 Among patients with MS treated with interferon beta-1b, higher 25(OH)D levels were associate

114 Among patients with MS mainly treated with interferon beta-1b, low 25(OH)D levels early in the dise

115 with HCV, exhibited increased expression of interferon-beta, 2',5'-oligoadenylate synthetase 1, inte

116 levels for interleukin 6 (IL-6) (+379%) and interferon-beta (+29%), which induce IFITM expression; l

117 ients given alemtuzumab, 2155 patients given interferon beta, 828 patients given fingolimod, and 1160

118 igh levels of ISG15, intrinsic or induced by interferon-beta, accelerate DNA replication fork progres

119 Analysis of a sample of recombinant human interferon-beta allowed the assignment of at least 18 gl

120 ium contrast-enhancing lesions compared with interferon beta alone and might reduce multiple sclerosi

121 T-cell proliferative response compared with interferon beta alone.

122 is disease activity to a greater extent than interferon beta alone.

123 apy of patients with multiple sclerosis with interferon beta, although high levels of IL-17F greater

124 or Clinical Excellence (NICE) concluded that interferon beta and glatiramer acetate would be cost eff

125 beta and low-dose daclizumab group p=0.002; interferon beta and high-dose daclizumab group p<0.0001)

126 an in the interferon beta and placebo group (interferon beta and low-dose daclizumab group p=0.002; i

127 hages is related to diminished production of interferon beta and may partly explain the involvement o

128 higher in both daclizumab groups than in the interferon beta and placebo group (interferon beta and l

129 nflammation and elevation of plasma level of interferon-beta and -gamma and interleukin-27.

130 Induction of Interferon-beta and Ccl4 by lipoproteins was also partia

131 TLR3 and TLR7/8, but not other TLRs, induced interferon-beta and interferon-lambda in bronchial epith

132 Defective Rhinovirus induced interferon-beta and interferon-lambda production has bee

133 high cure rates when combined with pegylated interferon-beta and ribavirin and show promising clinica

134 -/-), TIR-domain-containing adapter-inducing interferon-beta (-/-), and wild-type mice with toll-like

135 -/-), TIR-domain-containing adapter-inducing interferon-beta (-/-), and wild-type mice.

136 nce (TIR) domain-containing adapter-inducing interferon beta) and activation of the transcription fac

137 TRIF (TIR-domain-containing adapter-inducing interferon-beta), and affected interferon regulatory fac

138 proinflammatory cytokines interleukin 1beta, interferon beta, and RANTES (regulated on activation of

139 nscriptional induction of interleukin 1beta, interferon beta, and RANTES in ZIKV-infected podocytes a

140 Moreover, caspase-4, gasdermin D, interferon-beta, and cGAS levels were elevated in the RP

141 ency did not change in patients treated with interferon beta; and was more depleted after autologous

142 stant to ConA-induced liver damage, and anti-interferon beta antibody mitigated ConA/HSC-induced inju

143 ral analysis, as demonstrated using stressed interferon-beta as an example.

144 All patients were treated with intramuscular interferon-beta as part of the prospective study.

145 vitro culture of a microglial cell line with Interferon-beta, but not infected red blood cells, resul

146 Cytosolic DNA stimulates secretion of interferon-beta by cancer cells following activation of

147 AdRGD-PG-hIFNbeta vector encoding the human interferon-beta cDNA (hIFNbeta) was used to transduce hu

148 six drugs (remdesivir, lopinavir-ritonavir, interferon beta, corticosteroids, chloroquine and hydrox

149 receptor-domain-containing adapter-inducing interferon-beta-dependant interferon signaling pathways

150 receptor domain-containing adaptor-inducing interferon-beta-dependent chemokine interferon-gamma-ind

151 tor (TIR) domain-containing adapter-inducing interferon-beta-dependent response that also down-regula

152 ecule/TIR domain-containing adapter-inducing interferon-beta-dependent signaling pathways was further

153 ze a composite regulatory element within the interferon-beta enhancer (IFNb).

154 P-regulated enhancer and the virus-inducible interferon-beta enhancer.

155 ce displayed reduced Cox-2 protein, elevated interferon beta expression and increased caspase-3 activ

156 lic dinucleotide activation of STING induces interferon beta expression to initiate innate immune def

157 to one of the study therapies (alemtuzumab, interferon beta, fingolimod, or natalizumab), age 65 yea

158 ceived fingolimod (0.5/1.25 mg), placebo, or interferon beta for the respective study durations.

159 ientations in vitro had different effects on interferon-beta gene transcription when they were co-exp

160 Previously, this vector was used for interferon-beta gene transfer in mouse models of melanom

161 r long-range elements that interact with the interferon-beta gene, a model system for studying induci

162 n of cellular antiviral genes, including the interferon-beta gene, in response to Pattern Recognition

163 use, type, and timing of the following DMTs: interferon beta, glatiramer acetate, fingolimod, nataliz

164 Natalizumab, no treatment, interferon beta, glatiramer acetate, or fingolimod.

165 umab, rituximab, ocrelizumab) or injectable (interferon-beta, glatiramer acetate) DMTs.

166 initially treated with glatiramer acetate or interferon beta had a lower hazard of conversion to seco

167 probabilities of disability accumulation as interferon beta (hazard ratio [HR] 0.66 [95% CI 0.36-1.2

168 initial treatment with glatiramer acetate or interferon beta (HR, 0.66; 95% CI, 0.44-0.99; P = .046);

169 reduced the ability of nsp1beta to suppress interferon beta (IFN-beta) activation and also impaired

170 infected with H5N1 viruses, the induction of interferon beta (IFN-beta) and IFN-inducible genes, incl

171 aB heterodimers, which induce genes encoding interferon beta (IFN-beta) and other immune mediators.

172 1 (NS1) of WNV antagonizes the induction of interferon beta (IFN-beta) by interacting with and degra

173 n of signal transduction pathways leading to interferon beta (IFN-beta) gene induction following viru

174 are sensitive to cellular pretreatment with interferon beta (IFN-beta) in a dose-dependent manner.

175 ne (0DeltaNLS) is sensitive to inhibition by interferon beta (IFN-beta) in vitro and functions as a h

176 PRRSV nsp4, a 3C-like protease, antagonizes interferon beta (IFN-beta) production by cleaving the NF

177 , inhibiting virus-induced activation of the interferon beta (IFN-beta) promoter and interferon regul

178 lexes induced significantly higher levels of interferon beta (IFN-beta) than the polymerase complexes

179 f several inflammation biomarkers, including interferon beta (IFN-beta), interleukin-6 (IL-6), interl

180 on CRISPR screen in cells prestimulated with interferon beta (IFN-beta), we identified a small number

181 enhances their ability to produce IL-27 and interferon beta (IFN-beta).

182 Reovirus-infected neurons produce interferon beta (IFN-beta).

183 sential role in controlling the synthesis of interferon-beta (IFN-beta) and is a protein consisting o

184 erferon regulatory factor-1 (IRF1) to induce interferon-beta (IFN-beta) and subsequent autocrine sign

185 The induction of interferon-beta (IFN-beta) and/or IFN-lambda1 in respons

186 Further, we found that the cytokine interferon-beta (IFN-beta) can induce miR-1 expression i

187 ption factors essential in the activation of interferon-beta (IFN-beta) gene in response to viral inf

188 degradation of DDX41 and less production of interferon-beta (IFN-beta) in response to intracellular

189 The expression of interferon-beta (IFN-beta) in virus-infected HeLa cells

190 Interferon-beta (IFN-beta) is the major treatment for mu

191 ently triggers signaling pathways to promote interferon-beta (IFN-beta) production.

192 Oral administration of acetate mediated interferon-beta (IFN-beta) response by increasing expres

193 We show that lack of cytokine interferon-beta (IFN-beta) signaling causes spontaneous

194 nes such as interferon-gamma (IFN-gamma) and interferon-beta (IFN-beta), which can suppress excessive

195 ichia coli lipopolysaccharide, influenza, or interferon-beta (IFN-beta).

196 NF-kappaB, which promoted the production of interferon-beta (IFN-beta).

197 re incubated with interferon gamma (IFNG) or interferon beta (IFNB) and exposed to H pylori, includin

198 ic HMGB2 abundance and impaired induction of interferon beta (IFNB1) mRNA, which encodes a critical a

199 was found to be associated with the highest interferon beta (IFNbeta) and IL-33 levels in the nasal

200 family, via an autocrine mechanism involving interferon beta (IFNbeta) and IL-6.

201 with one of three alternative commonly used interferon beta (IFNbeta) disease modifying drugs: Avone

202 itin ligase Pellino1, which are required for interferon beta (IFNbeta) gene transcription.

203 Interferon beta (IFNbeta) has been reported to play an i

204 ssion of mRNA for TNF-alpha by 2-fold and of interferon beta (IFNbeta) in a PKR-dependent manner.

205 lidomide kills ABC DLBCL cells by augmenting interferon beta (IFNbeta) production, owing to the oncog

206 core in response to rituximab suggested that interferon beta (IFNbeta) was an important mechanistic c

207 Conversely, interferon beta (IFNbeta) was associated with decreased

208 s in the tumor and induce local secretion of interferon beta (IFNbeta), which is a pro-inflammatory c

209 the vesicular stomatitis virus (VSV)-murine interferon beta (IFNbeta)-sodium iodide symporter (NIS)

210 A single high dose of interferon-beta (IFNbeta) activates powerful cellular re

211 onocytes from B27-Tg rats also produced more interferon-beta (IFNbeta), which attenuated the effect o

212 otein 3 (NLRP3) inflammasome-independent and interferon-beta (IFNbeta)-resistant EAE (termed type B E

213 performed a genome-wide association study in interferon-beta (IFNbeta)-treated MS patients followed b

214 ing the expression of the antiviral cytokine interferon-beta (IFNbeta).

215 Alemtuzumab seems superior to fingolimod and interferon beta in mitigating relapse activity.

216 been associated with suboptimal response to interferon beta in patients with relapsing-remitting mul

217 lemtuzumab with natalizumab, fingolimod, and interferon beta in patients with relapsing-remitting mul

218 ed the transcription factor IRF3 and induced interferon-beta in a STING-dependent manner.

219 dendritic cells to induce interleukin-12 and interferon-beta in the context of both glycolipid presen

220 ed transcription of IFNB1, the gene encoding interferon-beta, in the stimulated cells.

221 c.2465G>A mutation enhanced MDA5 function in interferon beta induction.

222 ckdown of cGAS inhibited IRF3 activation and interferon-beta induction by DNA transfection or DNA vir

223 transcriptase, but not integrase, abrogated interferon-beta induction by the virus, suggesting that

224 Interferon-beta induction occurs during acute simian imm

225 Interferon beta (INFbeta) and glatiramer acetate (GA) ar

226 we tested our mutants' sensitivity to type I interferon (beta interferon [IFN-beta]) in restrictive c

227 us type 1 (HAstV-1) infection induces type I interferon (beta interferon [IFN-beta]) production in di

228 d to proinflammatory mediators (IL-12/IL-23, interferon beta, interferon gamma, CD40L) and platelet m

229 by inducing production of cytokines such as interferon-beta, interferon-gamma, and stimulating dendr

230 ntibodies directed against interferon-alpha, interferon-beta, interleukin-1alpha (IL-1alpha), IL-12p3

231 TRIF, TIR-domain-containing adapter-inducing interferon-beta; IRAK, IL-1R-associated kinase; TAK1, TG

232 n ConA-induced liver injury directly via the interferon-beta/IRF1 axis, and by modulating properties

233 Interferon beta is widely prescribed to treat multiple s

234 receptor domain-containing adapter-inducing interferon-beta is necessary to activate innate immunity

235 TRIF (TIR-domain-containing adapter-inducing interferon-beta) is essential for GN, but not systemic a

236 f WT, TIR domain-containing adapter-inducing interferon-beta knockout, and MyD88 adapter-like knockou

237 gh a combination of lopinavir, ritonavir and interferon beta (LPV/RTV-IFNb) is currently being evalua

238 Single-stranded RNA transcripts induced interferon-beta mediated though RIG-I and PKR activation

239 and MAVS in IBs inhibited the expression of interferon beta mRNA 27-fold following Newcastle disease

240 In addition, interferon-beta mRNA is present after activation with LT

241 nts with relapsing-remitting MS treated with interferon beta (n = 868) were compared with untreated c

242 large observational study of treatment with interferon beta or glatiramer acetate provide evidence t

243 le sclerosis activity despite treatment with interferon beta or glatiramer acetate, clinicians often

244 ltiple sclerosis and at least one relapse on interferon beta or glatiramer.

245 VS reduces this response 2-fold and blocking interferon beta or its receptor abrogates it.

246 Patients had received fingolimod, interferon beta, or glatiramer acetate for a minimum of

247 Interferon beta plays an important role in attenuation o

248 induced cytokine production and TRIF-induced interferon beta production.

249 res cyclic GMP-AMP synthase (cGAS)-dependent interferon-beta production and gasdermin D-dependent int

250 or-inducing interferon-beta (TRIF)-dependent interferon-beta production is crucial for caspase-11 act

251 tion placentas formed foci of infection, and interferon-beta production was prolonged.

252 at doses that do not induce Trex1 amplifies interferon-beta production, resulting in recruitment and

253 inhibits RIG-I stimulated IRF3 activity and interferon-beta production.

254 In contrast, TLR7 agonists induced a strong interferon beta response in the CNS but only low levels

255 1]) genomes and induces the inflammasome and interferon beta responses.

256 ral genomes and induces the inflammasome and interferon-beta responses.

257 regimens were well tolerated and stimulated interferon-beta secretion in tumors, induced tumor regre

258 equivalently sensitive to exogenously added interferon-beta, showed no evidence for differential rec

259 containing 2 (NOD2)-dependent activation of interferon-beta signaling and nuclear factor-kappaB.

260 TRIF (TIR domain-containing adapter-inducing interferon beta) signaling pathways.

261 fferentially active regulatory regions after interferon-beta stimulus, finding that using logistic re

262 In response to interferon-beta, the T387A mutant of STAT2 is much more

263 tor 4-TIR-domain-containing adapter-inducing interferon-beta (TLR4-TRIF).

264 Activation of Mertk synergized with interferon-beta to tighten cell junctions and prevent vi

265 t EDSS measurement) were as follows: for the interferon beta-treated cohort, 5.1 years (interquartile

266 Interferon-beta-treated cells expressing wild-type STAT2

267 The main outcome measure was time from interferon beta treatment eligibility (baseline) to a co

268 A multivariable Cox regression model with interferon beta treatment included as a time-varying cov

269 azard of disease progression associated with interferon beta treatment.

270 baseline, 6, 12 and 24 months after start of interferon-beta treatment.

271 r-domain-containing adaptor protein inducing interferon beta (TRIF) or myeloid differentiation factor

272 ), or TIR domain-containing adaptor inducing interferon beta (TRIF) signaling or an apoptosis-associa

273 8 and TIR-domain-containing adaptor-inducing interferon beta (TRIF), whereas palmitate-induced cerami

274 PK3), TIR-domain-containing adapter-inducing interferon-beta (TRIF) and Z-DNA-binding protein 1 (ZBP1

275 tor (TIR) domain-containing adapter-inducing interferon-beta (TRIF) but less so for signaling via mye

276 uired TIR-domain-containing adapter-inducing interferon-beta (TRIF) but were independent of myeloid-d

277 yD88)/TIR-domain-containing adapter-inducing interferon-beta (TRIF) double knockout littermates, we d

278 r domain containing adaptor protein inducing interferon-beta (TRIF) is an adaptor associated with TLR

279 ither TIR domain-containing adapter-inducing interferon-beta (TRIF) or MyD88 signal transduction.

280 8) or TIR-domain-containing adapter-inducing interferon-beta (TRIF) signaling pathways.

281 , the TIR-domain-containing adaptor-inducing interferon-beta (TRIF) was a central mediator of the res

282 receptor domain-containing adapter inducing interferon-beta (TRIF), a Toll-like receptor adapter pro

283 t the TIR domain containing adaptor-inducing interferon-beta (TRIF), an adaptor molecule mediating TL

284 ed by TIR-domain-containing adapter inducing interferon-beta (TRIF), but not by MyD88.

285 ta 1, TIR-domain containing adapter inducing interferon-beta (TRIF), TRIF-related adaptor molecule, i

286 ndent TIR-domain-containing adapter-inducing interferon-beta (TRIF), which function as cellular senso

287 -1R (TIR) domain-containing adapter-inducing interferon-beta (TRIF)-, TRIF-related adaptor molecule (

288 t and TIR-domain-containing adaptor-inducing interferon-beta (TRIF)-dependent interferon-beta product

289 ) and TIR domain-containing adaptor inducing interferon-beta (TRIF)-dependent signaling pathways, ini

290 - and TIR domain-containing adapter-inducing interferon-beta (TRIF)-dependent type I interferon produ

291 TRAM (TIR domain-containing adapter-inducing interferon-beta (TRIF)-related adaptor molecule), TRIF,

292 ) and TIR-domain-containing adaptor-inducing interferon-beta (TRIF).

293 the adapter TIR-containing adaptor inducing interferon-beta (TRIF).

294 , and TIR domain-containing adapter-inducing interferon-beta (TRIF).

295 -treated HSCs showed increased expression of interferon-beta, tumor necrosis factor-alpha, and CXCL1,

296 th relapsing-remitting MS, administration of interferon beta was not associated with a reduction in p

297 sease duration, and EDSS score), exposure to interferon beta was not associated with a statistically

298 version was lower when glatiramer acetate or interferon beta was started within 5 years of disease on

299 When glatiramer acetate or interferon beta were escalated to fingolimod, alemtuzuma

300 ependent expression of the antiviral protein interferon beta, whereas PAR2 negatively regulates expre